Curated By Nelson Vergel | ExcelMale.com | Updated March 2026
Key Takeaways
Retatrutide is a first-in-class triple hormone receptor agonist (GLP-1 + GIP + glucagon) from Eli Lilly, currently in Phase 3 clinical trials under the TRIUMPH program.
In Phase 3 (TRIUMPH-4), participants on the...
From the abstract:
Whether androgen deficiency among men increases the risk of cardiovascular (CV) events or is merely a disease marker remains a subject of intense scientific interest.
In this post hoc analysis of men with available baseline plasma T concentrations, we examined the...